Literature DB >> 10871647

Kappa opioids and TGFbeta1 interact in human endometrial cells.

E Chatzaki1, A N Margioris, A Makrigiannakis, E Castanas, V Georgoulias, A Gravanis.   

Abstract

The transforming growth factor beta1 (TGFbeta1) is a major regulator of human endometrial function. Human endometrium possesses specific opioid binding sites, the majority of which belong to the kappa type, for which the prodynorphin-derived opioids are the endogenous ligands. Since these two systems interact in several other tissues we postulated that opioids may affect the production of TGFbeta1 in human endometrium. We have found that kappa opioids exerted a time- and dose-dependent inhibitory effect on TGFbeta1 production from endometrial stromal and epithelial cells and from the Ishikawa human endometrial adenocarcinoma cell line. This effect was reversible by the specific opioid antagonist diprenorphine. To examine if this effect represents a paracrine endometrial response to locally produced kappa opioids we searched for the presence of the endogenous kappa opioid receptor ligands. Indeed, the prodynorphin transcript was detectable on Northern blots from normal and tumoral human endometrial cells; its size was that of the pituitary transcript, i.e. approximately 2.4 kb long. Most immunoreactive dynorphin from human endometrium had a molecular weight of 8 kDa. Finally, immunofluorescence staining of normal and tumoral human endometrial cells revealed the presence of dynorphin-positive cytoplasmic secretory granules. Taken together, our data suggest that in human endometrium, kappa opioids and the TGFbeta1 form a paracrine network which appears to be retained by the Ishikawa human endometrial adenocarcinoma cell line.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871647     DOI: 10.1093/molehr/6.7.602

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  5 in total

1.  Plasma endogenous enkephalin levels in early systemic sclerosis: clinical and laboratory associations.

Authors:  Terry A McNearney; K A Sluka; C Ahn; J D Reveille; Michael Fischbach; Maureen D Mayes
Journal:  Clin Exp Rheumatol       Date:  2010-06-10       Impact factor: 4.473

Review 2.  Psychological Stress and Functional Endometrial Disorders: Update of Mechanism Insights.

Authors:  Jin-Xiang Wu; Shu Lin; Shuang-Bo Kong
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-03       Impact factor: 5.555

3.  Developmental changes in the inhibition of cultured rat uterine cell proliferation by opioid peptides.

Authors:  J L Környei; Z Vértes; K A Kovács; P M Göcze; M Vértes
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

Review 4.  Neurogenic Inflammation in the Context of Endometriosis-What Do We Know?

Authors:  Renata Voltolini Velho; Eliane Taube; Jalid Sehouli; Sylvia Mechsner
Journal:  Int J Mol Sci       Date:  2021-12-03       Impact factor: 5.923

Review 5.  Opioids in cancer: The κ‑opioid receptor (Review).

Authors:  Qier Zhou; Zhiwei Zhang; Songkai Long; Wanjun Li; Baiyun Wang; Na Liang
Journal:  Mol Med Rep       Date:  2021-12-08       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.